GILD
GILEAD SCIENCES, INC.
NASDAQ · Healthcare · Drug Manufacturers - General · US
$153.07
−2.00%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$155.34
From 52W high−2.73%
Volume5.60M
Market cap$189.80B
P/E (TTM)—
P/S (TTM)6.2x
Div yield1.61%
Key dataOct 19, 2026
Open
$155.34
From 52W high
−2.73%
Volume
5.60M
Market cap
$189.80B
ValuationView details →
P/E (Fwd)
16.1x
EV/EBITDA
159.5x
P/E (TTM)
—
RSI (14)
59.9
MomentumView details →
1D Return
−2.00%
YTD Return
+25.99%
SummaryUpdated Jun 1, 2026
Gilead Sciences, Inc. (NASDAQ:GILD) is a leading biopharmaceutical company founded in 1987 and headquartered in Foster City, California. The company went public in 1992 and has established itself as a major player in the pharmaceutical industry, particularly known for its groundbreaking treatments in HIV/AIDS, hepatitis, and oncology. Gilead has built its reputation through innovative drug discovery and development, with a focus on addressing unmet medical needs in serious diseases. The company operates globally, serving patients in the United States, Europe, and international markets through its comprehensive portfolio of specialized medicines.
Similar companies
Latest newsMore news →
Gilead Sciences said it will present 28 research presentations, including two oral presentations, at Innoviva, Inc. 2026 on HIV treatment, prevention, and emerging antiviral programs.15h agoGILEAD SCIENCES, INC. reported that its pill succeeded in a mid-stage trial for bowel disease.17h agoGILEAD SCIENCES, INC. reported Phase 2 results showing its emvistegrast treatment produced a 23% placebo-adjusted clinical remission rate in patients with moderate to severe ulcerative colitis after a 200 mg daily dose for 12 weeks.19h ago